Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, anidulafungin (Ecalta®) cannot be endorsed for use within NHS Wales for the treatment of invasive candidiasis in paediatric patients aged 1 month to < 18 years. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | anidulafungin (Ecalta®) | |
| Formulation | 100 mg powder for concentrate for solution for infusion | |
| Reference number | 4587 | |
| Indication | Treatment of invasive candidiasis in paediatric patients aged 1 month to < 18 years |
|
| Company | Pfizer Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/11/2021 | |
| NICE guidance | AWMSG position statement on the appraisal of antimicrobial medicines |
|